Myocardial recovery in peri-partum cardiomyopathy after continuous flow left ventricular assist device by Lars H Lund et al.
CASE REPORT Open Access
Myocardial recovery in peri-partum
cardiomyopathy after continuous flow left
ventricular assist device
Lars H Lund1*, Karl-Henrik Grinnemo2, Peter Svenarud2, Jan van der Linden2 and Maria J Eriksson3
Abstract
Left ventricular assist devices (LVADs) offer effective therapy for severe heart failure (HF) as bridge to
transplantation or destination therapy. Rarely, the sustained unloading provided by the LVAD has led to cardiac
reverse remodelling and recovery, permitting explantation of the device. We describe the clinical course of a
patient with severe peri-partum cardiomyopathy (PPCM) rescued with a continuous flow LVAD, who experienced
recovery and explantation. We discuss assessment of and criteria for recovery.




Peri-partum cardiomyopathy (PPCM) affects one in 300
to one in 100,000 pregnant patients, depending on eth-
nic origin [1]. Risk factors include previous episode of
PPCM, multiparity and African ancestry. Causes are
poorly understood but prolactin and/or immune-
mediated mechanisms may be important. Therapy is
supportive although specific therapy with bromocriptine
may be beneficial. Prognosis is variable. In those that
survive without transplantation, LVEF may improve but
generally does not normalize [1].
Recovery with LVAD
In non-ischemic cardiomyopathy, myocardial injury may
be reversible. Sustained LV unloading from pulsatile
devices coupled with aggressive reverse-remodeling
pharmacologic therapy, possibly together with the b2-
agonist clenbuterol (the HARPS protocol), may permit
reversal of the molecular, cellular and structural remo-
deling seen in HF, and clinical recovery [2]. However, in
most reports, recovery is rare and often not sustained
[3,4], and PPCM and severe mitral regurgitation have
not been studied [2,5]. Recovery is thought to occur
mainly with pulsatile devices, but recently the HARPS
protocol with clenbuterol achieved success also with
continuous flow devices [5].
Criteria for and assessment of recovery
Recovery with device and prognosis after explant are
unpredictable. Prior to implantation, younger age and
shorter duration of HF but not LVEF or LVEDD predict
recovery [4,6]. Assessment of recovery requires turning
the LVAD “off”. Our protocol for the HeartMate II
entails ensuring an INR ≥ 2.0, titrating down to 8,000
rpm, administering intravenous heparin (200 units/kg)
and ensuring an activated clotting time > 400 at all
times that the rpm is below 8,000, followed by gradual
titration down to 6,000 rpm. This pump speed approxi-
mates zero forward flow [7]. Echocardiography, invasive
hemodynamics and the cardiopulmonary exercise test
are performed at 6,000 rpm and LVEF > 45 and LVEDD
< 55 mm coupled with preserved hemodynamics suggest
recovery [4,6]. The HARPS criteria have been estab-
lished as criteria for recovery (http://clinicaltrials.gov
identifier NCT00585546) (table 2) . Our patient met all
HARPS criteria except peak VO2 and ventilatory equiva-
lent for CO2 (VE/VCO2). We considered the peak VO2
adequate and attributed the very high VE/VCO2 to
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anxiety. The patient met several additional criteria for
recovery described by Dandel et al. [6].
Recovery in PPCM
LVAD-induced recovery in PPCM has to our knowledge
been described only in a handful of patients and all with
older pulsatile devices [8-10], and was excluded in the
series of Birks et al. [2,5]. Furthermore, right ventricular
disease is more severe in PPCM than in idiopathic
dilated cardiomyopathy [11] and pulsatile devices unload
the right ventricle more effectively than do non-pulsatile
devices, suggesting both that the benefits of an LVAD,
especially non-pulsatile, and the potential for recovery,
may be lower in PPCM. To our knowledge, recovery
with a non-pulsatile device has not previously been
described. Important for recovery is aggressive reverse
remodelling medical therapy, and assessment of recovery
requires down-titration of the pump coupled with inva-
sive and exercise testing.
We describe the clinical course of severe PPCM res-
cued with a continuous flow LVAD, who experienced
recovery and explantation. We discuss assessment of
and criteria for recovery.
Case Report
Pre-LVAD
The patient is a 37-year old African-American woman,
gravida 2 para 2, who presented to the Emergency
Department 8 days after normal spontaneous delivery
with severe dyspnea, pink frothy sputum and a respira-
tory rate of 44 per minute.
Blood pressure was 145/105 mm hg, heart rate regu-
lar at 105 per minute, O2 saturation was 88% on room
air and the patient was afebrile. Exam revealed
decreased breath sounds bilaterally and a faint systolic
murmur at the apex. EKG revealed sinus tachycardia.
Troponin T was < 0.01 microg/L, NT-proBNP was
2060 ng/L and D-dimer was 9.7 mg/L. Computed
tomography of the chest revealed widened vessels and
mild bilateral pleural effusions, but no pulmonary
embolism, and a cursory echocardiogram revealed left
ventricular ejection fraction (LVEF) of 10-15% and
moderate mitral regurgitation. The patient was intu-
bated and transferred to the thoracic intensive care
unit (ICU).
In the ICU, hemodynamics deteriorated, systolic blood
pressure was 70 mm Hg, LVEF was 5-10% and right
ventricular function deteriorated, and peripheral veno-
arterial extracorporeal membrane oxygenation (ECMO)
was instituted emergently. ECMO could not be weaned
although right ventricular function improved, and on
day 4, a continuous flow long-term left ventricular assist
device (LVAD, HeartMate II, Thoratec, Pleasanton, CA,
USA) was implanted as a bridge to transplant. Patient
data are listed in table 1.
Post-LVAD
Post-operative course was uneventful. The patient was
treated with aspirin 160 mg daily, warfarin adjusted to
an international normalized ratio (INR) of 2-3, and
ramipril, metoprolol, spironolactone and furosemide.
She engaged in structured aerobic exercise training 3
times per week.
At 6 months post-implantation the patient was in NYHA
I and we designed several weaning trials. We performed
echocardiography, invasive hemodynamics and cardiopul-
monary exercise testing with the pump set at baseline
9,000 revolutions per minute (rpm) and down-titrated to
6,000 rpm, with full heparinization (table 1). The patient
met all Harefield Recovery Protocol Study (HARPS) criteria
(table 2) except peak VO2 and ventilatory equivalent for
CO2 (VE/VCO2). We considered the peak VO2 adequate
and attributed the very high VE/VCO2 to anxiety.
Post LVAD explantation
Explantation was performed through median sternotomy
and left-sided thoracotomy on cardiopulmonary bypass
and a fibrillating heart. The inflow canula was removed,
the inside of the left ventricle was inspected for throm-
bus, and the defect in the left ventricle was sutured
directly. The outflow graft was cut and sutured near the
aorta. The patient was treated with milrinone, levosi-
mendan and inhaled nitric oxide prophylactically. Rami-
pril and metoprolol were restarted on day 4 and the
patient was discharged on day 32.
At last follow up, 18 months post explant (table 1),
she has remained stable in NYHA I-II. The degree of
secondary mitral regurgitation has worsened somewhat,
due to an asymmetrical LV contraction pattern, even
though QRS complexes remain narrow. Future follow-
up unless otherwise indicated will consist of monthly
physician visits, echocardiography every 3 months and
cardiopulmonary exercise testing every 6 to 12 months.
The patient is aware of the risk of gradual or even acute
deterioration and prepared for mitral valve intervention
or heart transplantation should this become necessary.
Conclusions
PPCM is uncommon but potentially severe. Recovery
may occur spontaneously but with cardiogenic shock
prognosis is poor. Recovery after LVAD placement is
poorly described and PPCM has been excluded from
most recovery series. Our observations raise the possibi-
lity of improving recovery and prognosis in PPCM with
early implantation of LVAD, perhaps also in moderately
severe cases.
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NYHA IV I-II I-II I-II – – – I-II
Hemodynamics
Systolic blood pressure, mm Hg 70 – – – – – 80 90
Mean blood pressure, mm Hg 40 95 80 85 180 130 - -
Diastolic blood pressure, mm Hg - – – – – – 50 60
Heart rate, beats/min 130 66 70 85 182 185 110 73
Cardiac index, L/min/m2 - - - 3.2 - 4.9 2.9 –
Pulmonary capillary wedge, mm
Hg
- - - 11 - 22 - –
Pulmonary artery systolic, mm Hg - - - 21 - 40 28 –
Pulmonary artery diastolic, mm
Hg
- - - 10 - 20 11 –
Central venous pressure, mm Hg - - - 4 - 11 13 –
Right ventricular stroke work
index, g/m2
- - - 366 - 416 87 -
Mixed venous O2 saturation, % - - - 67 - 27 61 –
LVAD monitor
Revolutions per minute – - 9000 6000 9000 6000 – –
Flow, L/min – - 5.3 “—” 6.6 “—” – –
Pulsatility index – - 5.4 6.2 3.7 6.3 – –
Exercise test
VO2, ml/(kg × min) – – – – – 15.3 – 15.5
VE/VCO2 – – – – – 75 – 35
Respiratory exchange ratio – – – – – 1.01 – 0.9
Laboratory
Creatinine, μmol/L 64 109 61 - - - 124 95
NT-proBNP, pg/mL 2060 - 137 - - - 6530 312
Troponin T, ng/mL < 0.01 - < 0.01 - - - 0.90 -
Echocardiography
Left ventricular ejection fraction,
%
10-15 70-75 75-80 70-75 75 70 60-70 55-60
Left ventricular end-diastolic
diameter, mm
- 42 37-40 39 42 37-40 35 51
Fractional shortening, % - 40 50 40 48 45 37 31
Right ventricular fractional area
change, %
- 35 38 40 - 39 - 32
Right ventricular end-diastolic
diameter, mm
- 28 27 27 23 22 27 29
Tricuspid regurgitation, grade, 1-4 - 2 < 1 < 1 - < 1 2 2
Tricuspid annular plane systolic
excursion, mm
- 8.5 9 9.5 - 10 11 15
E/A ratio - 2.2 1.6 2.8 - 1.8 1.6 2.5
E/E’ ratio - - 12 15 - 11 - 18
Left atrial diameter, mm - 25 31 31 32 30 23 46
Mitral regurgitation, grade, 1-4 3 1 1 1 - 1 1 3
Septum during systole - right right left right left left left
Aortic valve opening 1/1 1/1 1/1 1/1 1/1 1/1 1/1 1/1
- not available
– not applicable
“—” when flow is low, the HeartMate II controller does not estimate flow and the monitor instead displays “—”
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Consent
The patient has provided consent for this case report to
be published.
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Table 2 HARPS criteria.
Left ventricular end-diastolic diameter < 6 cm
Left ventricular end-systolic diameter < 5 cm
Left ventricular ejection fraction > 45%
Pulmonary capillary wedge pressure < 12 mm Hg
Cardiac Index > 2.8 L/min/m2
Peak VO2 (exercise) > 16 ml/kg/min
Ventilatory equivalent of CO2 (exercise) < 34
All criteria should be met with pump “off” (6000 rpm for HeartMate II)
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